The Broker's Prospectus: A Marketing Brochure, Not a Forensic Baseline

For years, the dental practice acquisition market has operated on a fundamental misunderstanding: that a broker’s prospectus is a due diligence document.

It is not. It is a marketing brochure. And if you are buying a practice based solely on its contents, you are not acquiring an asset. You are buying a faith-based multiple.

This isn’t an indictment of brokers. Most are well-meaning professionals trying to facilitate a transaction. Their job is to present the practice in the best possible light to attract buyers and maximize the seller’s return. That is a sales function. It is not a forensic function. And the distinction matters more than ever in a market where capital is expensive and operational clarity is paramount.

The faith-based multiple

Think about the consumer-protection standards for a $25,000 used car. You have the Carfax report. It tells you the history, the reported accidents, and the basic specs. But even with a clean Carfax, you wouldn’t dream of signing the title without taking the car to an independent mechanic for a thorough inspection.

Now compare that to a $1.5 million dental practice acquisition.

In the dental world, the broker’s prospectus is your Carfax. It tells you the history and the reported numbers. But for the vast majority of dentists, that is where the diligence ends. They buy the practice based on the reported accidents and a prayer.

We have higher transparency standards for a used Ford than we do for a seven-figure clinical asset.

No rational person would buy a car with the level of diligence that the vast majority of dentists use to buy their practices. Buyers are presented with a marketing brochure that highlights revenue, profit, and a few cherry-picked KPIs. They are told what the practice could be. They are rarely shown what the practice actually is at a forensic level.

A faith-based multiple is a valuation derived from numbers that have not been independently verified, stress-tested, or reconciled against raw clinical data. It is a multiple based on belief, not on baseline.

What the prospectus doesn’t tell you

The broker’s prospectus is designed to sell. It will tell you the practice’s collections, its overhead, and its net income. It will show you a P&L that looks healthy. But it will almost never show you the data that truly matters for an institutional-grade evaluation.

What the prospectus shows	What it hides	Why it matters
A large active patient count	Patients not seen in 18–24 months	You can’t pay a premium on a patient base that doesn’t exist
Production totals	The real case acceptance rate	Diagnosed treatment that walked out — often the gap between ~48% and ~75%
The selling doctor’s production	Provider dependency	Revenue tied to the owner’s hands leaves when they do
Reported collections	Fee-schedule / PPO exposure	Write-offs and one dominant plan can quietly gut profitability

Source: Precision Dental Analytics forensic reviews. Case-acceptance benchmarks (~48% industry average vs. ~75% institutional-grade) per PDA benchmarking.

Take the active patient count. The prospectus will often cite a large number — but a forensic review frequently reveals that it includes hundreds of patients who have not been seen in two years or more. The practice-management software counted them; the buyer is not going to pay a premium multiple on a patient base that does not actually exist.

The real case acceptance rate is perhaps the most critical operational metric, yet it is almost never included. They show you production; they do not show you how much diagnosed and presented treatment walks out the door without being scheduled. An industry average of 48% versus a benchmark of 75% represents millions in uncaptured revenue. This is not fraud — it is a structural blind spot in the conventional advisory process.

The illusion of due diligence

Buyers are often told that their lender’s underwriting, their attorney’s review of the purchase agreement, and their CPA’s tax analysis constitute due diligence.

This is an illusion.

Each of these professionals performs a critical function, but none of them are conducting a forensic operational review of the clinical data. They are looking at the financial outputs, the legal framework, and the tax implications. They are not looking at the clinical engine that drives the practice.

This is why buyers often feel blindsided months after closing. The P&L looked good. The loan closed. The legal documents were signed. But the practice isn’t performing as expected. The case acceptance is low. The schedule is full of holes. The hygiene department is churning. And the buyer is left wondering what they missed.

They didn’t miss anything. The information was never presented. And the conventional advisory ecosystem was never designed to provide it.

Clinical data as the new baseline

The era of buying a dental practice on faith is ending. Capital is too expensive. Competition is too fierce. And the stakes are too high.

The smartest buyers are no longer relying on marketing brochures. They are demanding a forensic baseline. They are asking for raw procedure-code level data. They are analyzing case acceptance rates, hygiene retention, and provider productivity. They are quantifying the operational gaps and the uncaptured opportunity. They are building their own valuation based on clinical reality, not on a broker’s projection.

This is the same discipline a seller should run on themselves before going to market — the forensic baseline behind a defensible number, not the story a spreadsheet tells.

This isn’t about killing deals. It’s about making better ones. It’s about walking into a practice on Day 1 with operational clarity, knowing exactly what you’ve bought, and having a roadmap to unlock its full potential.

It’s about replacing the faith-based multiple with a data-driven one.

You cannot protect what you have not quantified.

---

About the author — Joe DeLuca is Chief Analytics Officer and co-principal of Precision Dental Analytics, where he builds the benchmarking architecture behind the firm’s M&A defense and growth work. He is the author of The Root of Leadership.